Navigation Links
Vermillion Receives NASDAQ Notice of Non-Compliance
Date:2/27/2008

FREMONT, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML) announced that on February 22, 2008 it received a letter from The NASDAQ Stock Market LLC that indicated the Company is not in compliance with Marketplace Rule 4310(c)(3), which requires it to have (i) a minimum of $2,500,000 in stockholders' equity; (ii) $35,000,000 in market value of listed securities; or (iii) $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.

In accordance with Marketplace Rule 4310(c)(8)(C), the Company has been afforded 30 calendar days, or until March 24, 2008, to regain compliance. If, any time prior to March 24, 2008, the market value of listed securities of the Company's common stock is $35,000,000 or more for a minimum of 10 consecutive business days, NASDAQ may determine that the Company has regained compliance. If the Company does not regain compliance by March 24, 2008, NASDAQ will provide written notification that the Company's securities are subject to delisting. At that time, the Company may request a hearing before a NASDAQ Listing Qualifications Panel. The Company's securities would remain listed pending the issuance of a decision by the Panel.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, hematology, cardiology and women's health with an initial focus in ovarian cancer. Vermillion is based in Fremont, California. Additional informatio
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
2. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
5. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
6. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
7. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
8. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
9. Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg
10. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... As part of its 2015 growth plan ... and technical service business units, Whitehouse Laboratories is pleased to announce that ... adjacent to the Container Center of Excellence and will be strictly dedicated to basic USP ...
(Date:7/29/2015)... According to a new market research ... Forecasts (2015-2020), , published by Mordor Intelligence, the Global market ... end of 2020, with North America ... of the global market size. The Global market for Stem ... during the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... QIAGEN assay for JAK2 V617F mutation aims to identify patients ... monitor responses to therapy - Lilly will co-develop ... biomarker underpins potential future expansion with additional Pharma compounds targeting ... Prime Standard: QIA) today announced that it has entered into ...
... at Northwestern University have created a new kind ... in the terahertz range. Though this design ... visible spectrum, it could have implications in diagnostics, ... Cheng Sun, assistant professor of mechanical engineering at ...
...  Sept. 2, 2011  PTC Therapeutics, Inc. and ... of their collaboration. Under the original agreement, PTC ... and Genzyme held commercial rights in all other ... rights to ataluren and Genzyme retains an option ...
Cached Biology Technology:QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 3QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 4Hiding objects with a terahertz invisibility cloak 2PTC Therapeutics and Genzyme Announce Restructuring of Collaboration 2PTC Therapeutics and Genzyme Announce Restructuring of Collaboration 3
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... In almost 90 per cent of cases, novel drugs tested on ... be scrapped. Often the drugs do not work, while at ... now shows that this number can be reduced. The secret is ... In 1993, five out of 15 liver patients who participated ...
... A laboratory study has shown for the first time that ... a side-effect of some statin drugs - an increased risk ... widely prescribed drugs in the world, able to reduce LDL, ... or other cardiovascular events. However, their role in raising the ...
... call of the Seventh Framework Programme (FP7) of the ... from 17 countries, has received a 8M funding ... the largest European ,biobanks,. The project represents ... BBMRI (Biobanking and Biomolecular Resources Research Infrastructure), which was ...
Cached Biology News:New cutting-edge cell research will lead to safer medical experiments on humans 2New cutting-edge cell research will lead to safer medical experiments on humans 3New cutting-edge cell research will lead to safer medical experiments on humans 4Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes 28 M € from EU to enhance access by scientists to the largest European 'biobanks' 2
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
... Rabbit monoclonal [EP282Y] to ... for all tested applications). ... peptide corresponding to residues in ... synthetase. Entrez ...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: